OSAKA/TOKYO -- Japanese drugmaker Shionogi said Wednesday that it will acquire Torii Pharmaceutical and other assets from Japan Tobacco in a deal worth around 160 billion yen ($1.1 billion ...

Shares of Japanese drugmaker Shionogi & Co. dropped the most in almost a month after the Nikkei newspaper reported the company will buy Torii Pharmaceutical Co. for about ¥150 billion ($1 billion).

TOKYO, May 7 (Reuters) - Japanese drugmaker Shionogi (4507.T), opens new tab said on Wednesday that it will acquire Torii Pharmaceutical (4551.T), opens new tab, a subsidiary of Japan Tobacco ...

Investors might want to bet on Shionogi & Co., Ltd. Unsponsored ADR (SGIOY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic aimed at protecting vulnerable populations from Covid-19. The funding ...

Michael N. Dudley, PharmD, President and CEO of Qpex Biopharma SAN DIEGO—Shionogi plans to create its first discovery lab in the United States, with a focus on antimicrobial and pandemic ...

New U.S. Facility, Established Through Qpex Biopharma, Inc., a Shionogi Group Company, Will Increase Capabilities in Infectious Disease and Pandemic Preparedness OSAKA, Japan, June 03, 2024 ...

The Microsoft Surface Pro 11 could be the most exciting Surface Pro in ages. Not only does it sport an OLED panel, but it also features the new Qualcomm Snapdragon X processors — both of which ...

Tokyo: Japan's Shionogi & Co said on Monday its pill-based treatment for COVID-19 did not meet the primary endpoint of showing a statistically significant reduction of 15 common symptoms of the ...

The company's pivotal Phase 3 study of ensitrelvir did however demonstrate a potent antiviral effect compared to placebo, the company said. WHY IT'S IMPORTANT Shionogi said previously it expected ...

OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D ...

Shionogi & Co and Maze Therapeutics have announced an exclusive worldwide licensing agreement for an investigational Pompe disease therapy. Estimated to affect about one in 40,000 people in the US, ...